[
    [
        {
            "time": "2018-03-21",
            "original_text": "Dow Drops 771 Points This Week as Tariffs, Powell Rough Up Stocks",
            "features": {
                "keywords": [
                    "Dow",
                    "drops",
                    "tariffs",
                    "Powell"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Dow Drops 771 Points This Week as Tariffs, Powell Rough Up Stocks",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-21",
            "original_text": "Biogen, AbbVie Pull Multiple Sclerosis Drug On Inflammation Reports",
            "features": {
                "keywords": [
                    "Biogen",
                    "AbbVie",
                    "multiple sclerosis",
                    "drug",
                    "inflammation"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Biogen, AbbVie Pull Multiple Sclerosis Drug On Inflammation Reports",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-21",
            "original_text": "3 Top Dividend Stocks to Buy Right Now",
            "features": {
                "keywords": [
                    "dividend",
                    "stocks",
                    "buy"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Top Dividend Stocks to Buy Right Now",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-21",
            "original_text": "Biogen and Abbvie Take Multiple Sclerosis Drug Off Market",
            "features": {
                "keywords": [
                    "Biogen",
                    "Abbvie",
                    "multiple sclerosis",
                    "drug",
                    "market"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Biogen and Abbvie Take Multiple Sclerosis Drug Off Market",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-21",
            "original_text": "Notable ETF Inflow Detected - MTUM, BA, ABBV, AMAT",
            "features": {
                "keywords": [
                    "ETF",
                    "inflow",
                    "MTUM",
                    "BA",
                    "ABBV",
                    "AMAT"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Notable ETF Inflow Detected - MTUM, BA, ABBV, AMAT",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-21",
            "original_text": "Nasdaq, S&P 500 Turn Positive But Dow Closes Lower - U.S. Commentary",
            "features": {
                "keywords": [
                    "Nasdaq",
                    "S&P 500",
                    "Dow",
                    "positive",
                    "lower"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "Nasdaq, S&P 500 Turn Positive But Dow Closes Lower - U.S. Commentary",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-21",
            "original_text": "Multiple Sclerosis Relapse Drug Is Pulled After Patient Safety Concerns",
            "features": {
                "keywords": [
                    "multiple sclerosis",
                    "drug",
                    "pulled",
                    "safety concerns"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Multiple Sclerosis Relapse Drug Is Pulled After Patient Safety Concerns",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-21",
            "original_text": "8 Dividend Payouts That Are Soaring on Tax Cuts",
            "features": {
                "keywords": [
                    "dividend",
                    "payouts",
                    "soaring",
                    "tax cuts"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "8 Dividend Payouts That Are Soaring on Tax Cuts",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-21",
            "original_text": "Major Averages Turn Mixed After Seeing Initial Weakness - U.S. Commentary",
            "features": {
                "keywords": [
                    "major averages",
                    "mixed",
                    "weakness"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "Major Averages Turn Mixed After Seeing Initial Weakness - U.S. Commentary",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-21",
            "original_text": "Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis",
            "features": {
                "keywords": [
                    "Biogen",
                    "AbbVie",
                    "withdrawal",
                    "ZINBRYTA",
                    "multiple sclerosis"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]